The Omega-3 Index: What the Test Measures, and Why the Cardiovascular Trial Evidence Is More Mixed Than It Looks

This article is for educational purposes and is intended for healthcare practitioners and informed readers. It does not constitute medical advice. Any decision to start, stop, or adjust omega-3 fatty acid supplementation, particularly in a patient with known cardiovascular disease or who is taking anticoagulant or antiplatelet medication, should be made with a treating clinician.

Why Practitioners Order This Test

The Omega-3 Index measures the combined eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content of red blood cell membranes, expressed as a percentage of total membrane fatty acids. Because red blood cells turn over roughly every 120 days, the index reflects dietary and supplemental omega-3 intake over the preceding three to four months rather than a single recent meal, which is the main practical advantage it has over a one-off serum or plasma fatty acid measurement. The test is a reasonable addition to a functional workup in patients with cardiovascular risk factors or low dietary fish intake, but what a given result should prompt a clinician to do is less settled than the marketing around the test often implies, and that is the part of the picture this article focuses on.

Where the Risk Association Comes From

The index itself, and the idea that roughly 8% or higher is cardioprotective while 4% or lower marks higher risk, originates with William Harris and Clemens von Schacky's proposal of the Omega-3 Index as a risk factor for coronary heart disease death in 2004. The strongest subsequent evidence for this association comes from a 2017 analysis in Atherosclerosis by Harris, Del Gobbo, and Tintle, which pooled data across 10 prospective cohort studies. It reported a hazard ratio of 0.85 for fatal coronary heart disease per one standard deviation increase in the Omega-3 Index, and estimated that moving from an index of 4% to 8% was associated with roughly a 30% reduction in fatal coronary heart disease risk.

That is a genuinely strong observational association, replicated across cohorts including the Framingham Offspring Study and the Women's Health Initiative. It is also, on its own, not proof that raising a patient's Omega-3 Index through supplementation will lower their cardiovascular event risk. Cohort associations can reflect confounding (people with a higher Omega-3 Index also tend to eat more fish, exercise more, and smoke less) rather than a direct causal effect of the fatty acids themselves. Establishing that requires randomized trials, and this is where the evidence becomes genuinely more complicated, not less, as the trial base has grown.

The Randomized Trial Evidence: Four Outcomes, Four Different Answers

REDUCE-IT: A Large Benefit, in a Specific Population, With a Specific Formulation

REDUCE-IT, published by Bhatt and colleagues in the New England Journal of Medicine in 2019, randomized 8,179 statin-treated patients with elevated triglycerides (135 to 499 mg/dL) and either established cardiovascular disease or diabetes plus additional risk factors to icosapent ethyl (a purified, stabilized EPA ethyl ester) 4 g/day or placebo. The primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina) occurred in 17.2% of the icosapent ethyl group versus 22.0% of the placebo group, a hazard ratio of 0.75 (95% CI, 0.68 to 0.83; P<0.001). Cardiovascular death specifically was also reduced (hazard ratio 0.80, 95% CI 0.66 to 0.98).

This is a large, statistically robust effect in a trial that was not stopped early and met its pre-specified endpoints. It is also a trial of one specific formulation (purified EPA alone, not a mixed EPA+DHA product) in one specific population (high triglycerides, already on statin therapy, mostly with established cardiovascular disease). Extrapolating the result to a different formulation or a lower-risk population is not supported by this trial, and the next trial in this list is the clearest demonstration of why.

STRENGTH: A Mixed EPA+DHA Formulation, Stopped Early for Futility

STRENGTH, published by Nicholls and colleagues in JAMA in 2020, enrolled a similarly high-risk population (13,078 statin-treated patients with high triglycerides and low HDL cholesterol) and randomized them to 4 g/day of a carboxylic acid formulation containing both EPA and DHA (omega-3 CA), or corn oil. The trial was halted early on the recommendation of its data monitoring committee after an interim analysis showed a low probability of benefit. The primary composite endpoint occurred in 12.0% of the omega-3 CA group versus 12.2% of the corn oil group, a hazard ratio of 0.99 (95% CI, 0.90 to 1.09; P=0.84), essentially no difference. Gastrointestinal adverse events were notably more common with the active treatment (24.7% versus 14.7%).

A subsequent secondary analysis of STRENGTH, published by Nissen and colleagues in JAMA Cardiology in 2021, directly addressed whether patients who achieved a high blood EPA or DHA level still benefited. Among more than 10,000 participants with 12-month fatty acid level data, the adjusted hazard ratios for the highest tertile of achieved EPA and DHA levels were 0.98 and 1.02 respectively, neither statistically significant. In other words, even patients whose blood omega-3 levels rose substantially on treatment, the mechanism an Omega-3 Index test is meant to track, showed no reduction in cardiovascular events in this trial. That finding matters for how the Omega-3 Index itself should be interpreted: achieving a numerically higher index through this particular formulation did not translate into fewer events in this population, which complicates any assumption that the index level is itself the thing worth treating to, independent of which product and population are involved.

Some cardiologists, including STRENGTH's own lead investigator Steven Nissen, have argued publicly that the difference between REDUCE-IT's mineral oil placebo and STRENGTH's corn oil placebo may have contributed to the diverging results, since mineral oil is not fully biologically inert and could in theory have modestly worsened lipid or inflammatory markers in the REDUCE-IT control arm. This remains a genuinely disputed point among trialists and has not been resolved by a head-to-head comparison; it does not, on its own, explain why even the highest achieved blood omega-3 levels failed to show benefit within STRENGTH itself.

VITAL: A General Population, No Significant Primary Benefit

VITAL, published by Manson and colleagues in the New England Journal of Medicine in 2019, took a different approach: a primary-prevention trial in 25,871 generally healthy US adults (not selected for high triglycerides or existing cardiovascular disease) randomized to 1 g/day of a mixed EPA+DHA fish oil or placebo, in a factorial design that also tested vitamin D. The primary cardiovascular composite endpoint (myocardial infarction, stroke, or cardiovascular death) was not significantly reduced by omega-3 supplementation overall.

This is an important data point specifically because it is the trial most similar to how omega-3 supplementation is actually used in general naturopathic and integrative practice: a modest dose of a mixed fish oil product given to patients without a specific lipid abnormality, for general cardiovascular risk reduction. In that setting, the trial evidence does not support an expectation of benefit on hard cardiovascular outcomes, a materially different picture from the specific, high-risk, high-dose REDUCE-IT population.

OMEMI: Elderly Post-Myocardial Infarction Patients, Also Negative

OMEMI, published by Kalstad and colleagues in Circulation in 2021, randomized 1,027 elderly patients (aged 70 to 82) who had recently had a myocardial infarction to 1.8 g/day of EPA+DHA or placebo. The composite primary endpoint showed no significant difference between groups, and the trial's authors noted a signal toward more new-onset atrial fibrillation in the omega-3 group, consistent with what has since been confirmed at a larger scale, discussed below.

What the Four Trials Together Suggest

Laid side by side, these four trials do not describe a single compound with a single dose-response relationship to cardiovascular risk. They describe at least two different products (purified EPA versus mixed EPA+DHA formulations) tested in at least three different populations (high-triglyceride secondary-prevention patients, general healthy adults, and elderly post-MI patients), with results ranging from a large, robust benefit to clearly null. The honest synthesis is that formulation and patient selection, not "omega-3 fatty acids" as an undifferentiated category, appear to be the variables that best explain why REDUCE-IT succeeded where STRENGTH, VITAL, and OMEMI did not. A naturopathic or functional practitioner reading "omega-3s reduce cardiovascular risk" as a single, unqualified claim, or treating a general multigram fish oil recommendation as equivalent to a trial-tested prescription EPA product in a high-triglyceride statin-treated patient, is extending the evidence further than the trial data actually supports.

The Atrial Fibrillation Signal Is Real and Dose-Related

A consistent safety signal across these trials, and across the omega-3 literature more broadly, is an increased risk of atrial fibrillation with higher-dose supplementation. A 2021 systematic review and meta-analysis by Gencer and colleagues in Circulation, pooling seven randomized cardiovascular outcome trials (including REDUCE-IT, STRENGTH, and VITAL) covering roughly 81,000 patients, found that marine omega-3 fatty acid supplementation was associated with a significantly increased risk of atrial fibrillation (hazard ratio 1.25, 95% CI 1.07 to 1.46), with the risk rising with dose and most apparent above 1 g/day. This is a relevant consideration for any patient being counselled toward higher-dose omega-3 supplementation, particularly those with existing risk factors for atrial fibrillation, and is a reasonable topic to discuss explicitly alongside any decision to pursue gram-level dosing, the range used in REDUCE-IT and STRENGTH, rather than the lower doses used in general supplementation.

Practical Implications for Interpreting the Test

Taken together, the honest clinical position is this: the Omega-3 Index is a reasonably well-validated biomarker of long-term omega-3 status and tracks with cardiovascular risk in observational data, and a very low result (below roughly 4%) is a legitimate prompt to address dietary omega-3 intake. What the index result does not do, on its own, is tell a clinician which intervention, at which dose, in which patient, will translate a low number into a lower cardiovascular event rate, because the trial evidence shows that outcome depends heavily on the specific product and population, not simply on raising the number. For a patient resembling the REDUCE-IT population (statin-treated, elevated triglycerides, established cardiovascular disease or diabetes with additional risk factors), the trial evidence for purified EPA is genuinely strong. For a general patient without that risk profile, VITAL and OMEMI do not support an expectation that routine supplementation will reduce hard cardiovascular endpoints, even though correcting a low Omega-3 Index may still have a reasonable rationale for other outcomes not covered by these four trials, such as triglyceride lowering itself, inflammatory markers, or the separate evidence base for omega-3s in mood and cognitive health. Ordering the test without a clear plan for what a given result will change in the treatment plan, and without being specific with the patient about which product and dose the evidence actually supports, is the gap worth closing in practice. For related evidence-based approaches to cardiovascular and mitochondrial support in naturopathic practice, see our review of CoQ10 and ubiquinol, and for a parallel example of a commercial functional test whose popularity has outpaced a straightforward evidence picture, see our review of IgG food sensitivity testing.

Clinical Summary

The Omega-3 Index is a legitimate, reasonably well-validated biomarker of long-term EPA and DHA status, and lower levels are associated with higher cardiovascular risk in large observational cohorts. However, the randomized trial evidence on whether supplementing to raise that number actually prevents cardiovascular events is genuinely mixed and formulation- and population-specific: purified EPA (icosapent ethyl) produced a large, statistically robust benefit in high-triglyceride, statin-treated, high-risk patients in REDUCE-IT, while a mixed EPA+DHA formulation in a similar high-risk population (STRENGTH) and mixed EPA+DHA supplementation in general healthy adults (VITAL) and in elderly post-myocardial-infarction patients (OMEMI) showed no significant cardiovascular benefit, including, in STRENGTH's secondary analysis, among patients who achieved the highest blood omega-3 levels on treatment. Higher-dose supplementation across these trials is also associated with a real, dose-related increase in atrial fibrillation risk. Practitioners using the Omega-3 Index should treat a low result as a prompt for a specific, evidence-matched intervention appropriate to that patient's actual risk profile, rather than as justification for a generic high-dose fish oil recommendation presented as having the same trial support as the REDUCE-IT population and product.

References

• Harris WS, Del Gobbo L, Tintle NL. "The Omega-3 Index and relative risk for coronary heart disease mortality: Estimation from 10 cohort studies." Atherosclerosis. 2017;262:51-54. DOI: 10.1016/j.atherosclerosis.2017.05.007. PMID: 28511049.
• Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. "Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia." New England Journal of Medicine. 2019;380(1):11-22. DOI: 10.1056/NEJMoa1812792. PMID: 30415628.
• Nicholls SJ, Lincoff AM, Garcia M, et al. "Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial." JAMA. 2020;324(22):2268-2280. DOI: 10.1001/jama.2020.22258. PMID: 33190147.
• Nissen SE, Lincoff AM, Wolski K, et al. "Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk: A Secondary Analysis of the STRENGTH Trial." JAMA Cardiology. 2021;6(8):910-917. DOI: 10.1001/jamacardio.2021.1157. PMID: 33993205.
• Manson JE, Cook NR, Lee IM, et al; VITAL Research Group. "Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer." New England Journal of Medicine. 2019;380(1):23-32. DOI: 10.1056/NEJMoa1811403. PMID: 30415637.
• Kalstad AA, Myhre PL, Laake K, et al; OMEMI Investigators. "Effects of n-3 Fatty Acid Supplements in Elderly Patients After Myocardial Infarction: A Randomized, Controlled Trial." Circulation. 2021;143(6):528-539. DOI: 10.1161/CIRCULATIONAHA.120.052209. PMID: 33191772.
• Gencer B, Djousse L, Al-Ramady OT, Cook NR, Manson JE, Albert CM. "Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis." Circulation. 2021;144(25):1981-1990. DOI: 10.1161/CIRCULATIONAHA.121.055654. PMID: 34612056.

This article is intended for educational purposes and professional practice reference. It does not constitute individual medical advice. Omega-3 supplementation decisions, particularly at gram-level doses or in patients with cardiovascular disease, atrial fibrillation risk, or anticoagulant therapy, should be made in consultation with a qualified healthcare provider.